Literature DB >> 8097831

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

H L McLeod, D R Miller, W E Evans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8097831     DOI： 10.1016/0140-6736(93)93168-z

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  25 in total

1.  Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.

Authors:  B A Kaskas; E Louis; U Hindorf; E Schaeffeler; J Deflandre; F Graepler; K Schmiegelow; M Gregor; U M Zanger; M Eichelbaum; M Schwab
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

3.  The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.

Authors:  Takaya Moriyama; Rina Nishii; Ting-Nien Lin; Kentaro Kihira; Hidemi Toyoda; Nersting Jacob; Motohiro Kato; Katsuyoshi Koh; Hiroto Inaba; Atsushi Manabe; Kjeld Schmiegelow; Jun J Yang; Hiroki Hori
Journal:  Pharmacogenet Genomics       Date:  2017-06       Impact factor: 2.089

4.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.

Authors:  H L Tai; E Y Krynetski; E G Schuetz; Y Yanishevski; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 5.  Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.

Authors:  E Y Krynetski; W E Evans
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 6.  [Implications of pharmacogenetics in every-day practice].

Authors:  T Gerloff; I Roots
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

7.  Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

8.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

Review 9.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 10.  Chemotherapy individualization.

Authors:  Gareth J Veal; Sally A Coulthard; Alan V Boddy
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.